Artificial intelligence in clinical trials.

Episode 1

In this episode Blair is joined by his colleague Tam Nguyen, who wears a number of different hats in his various roles. Along with being a Resident Director of Acclime Australia and supporting many life sciences companies with their clinical trial programs here in Australia, Tam is also Deputy Director of Clinical Research at St Vincent’s Hospital in Melbourne, holds a number of Associate Professorships and Adjunct Associate Professorships at RMIT, Monash University, and Melbourne University, and is also an expert advisor and board member of a number of organisations in Melbourne.

We are also very excited to be joined by the wonderful Michelle Gallaher, who generously shares her experiences as an award-winning health technology entrepreneur, speaker and advocate. Michelle’s 25+ year career spans startups, biotech and pharma marketing roles, national medical research initiatives and leading a biotech peak-body. She is currently the CEO of the ASX-listed Opyl Ltd, which is an innovative tech company working at the intersection of social media, clinical trials, and artificial intelligence.

Some of the key discussion points in this episode:

  1. Key steps and considerations that a drug development company and a clinical research organisation need to consider
  2. How AI is going to shake up the Clinical Trials sector
  3. Impact of AI in Clinical Trials
  4. Confidentiality and privacy in the Clinical Trial space

Listen to the podcast on:

Episode 2

Culture-driven governance

© Acclime Australia | Privacy policy

Liability limited by a scheme approved under Professional Standards Legislation.